Back to top
more

OPKO Health (OPK)

(Delayed Data from NSDQ)

$1.48 USD

1.48
10,271,474

-0.11 (-6.92%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $1.51 +0.03 (2.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

OPKO Health's (OPK) Q3 Earnings, Revenues Top Estimates

by Zacks Equity Research

OPKO Health's (OPK) third-quarter results benefit from strength in its Pharmaceuticals segment, backed by robust RAYALDEE sales.

OPKO Health (OPK) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of 500.00% and 26.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

OPKO (OPK) BLA Review for Growth Hormone Deficiency Drug Delayed

by Zacks Equity Research

The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer's BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The review period has been further extended by three months.

OPKO Health (OPK) Forms JV, Establishes Presence in China

by Zacks Equity Research

OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.

OPKO Health's (OPK) Arm Boosts Prenatal Screening With Buyout

by Zacks Equity Research

OPKO Health's (OPK) BioReference's acquisition to expand its NIPS offerings and thereby enhance prenatal screening.

OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down

by Zacks Equity Research

OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.

OPKO Health (OPK) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of -250.00% and -3.31%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: OPKO Health (OPK) Q2 Earnings Expected to Decline

by Zacks Equity Research

OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OPKO Health (OPK) Inks Licensing Deal for AntagoNAT Technology

by Zacks Equity Research

OPKO Health's (OPK) latest licensing agreement is expected to advance the development and commercialization of potential disease-modifying therapeutics, especially for Dravet syndrome.

OPKO Health (OPK) and Nicoya Sign RAYALDEE Deal

by Zacks Equity Research

OPKO Health's (OPK) subsidiary EirGen Pharma to develop and commercialize RAYALDEE in Greater China in collaboration with an affiliate of Nicoya Therapeutics.

OPKO Health (OPK) Inks Agreement to Sell Its Ireland Facility

by Zacks Equity Research

OPKO Health (OPK) expects to improve its business efficacy and focus on oral solid dose products post the sale of its Ireland facility.

    Why Is OPKO Health (OPK) Down 5.6% Since Last Earnings Report?

    by Zacks Equity Research

    OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Is the Options Market Predicting a Spike in OPKO Health (OPK) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.

    OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top

    by Zacks Equity Research

    OPKO Health's (OPK) first-quarter results benefit from strength in diagnostics.

    OPKO Health (OPK) Meets Q1 Earnings Estimates

    by Zacks Equity Research

    OPKO Health (OPK) delivered earnings and revenue surprises of 0.00% and 8.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    OPKO Health's (OPK) BioReference Extends Sports Partnerships

    by Zacks Equity Research

    OPKO Health's (OPK) BioReference expands its major league sports relationships with the announcement of COVID-19 testing agreement with MLB.

    OPKO Health (OPK) BioReference Extends COVID-19 School Testing

    by Zacks Equity Research

    OPKO Health's (OPK) BioReference expands COVID-19 testing in schools to create a safer learning environment for students, teachers, staff and their families.

    OPKO Health (OPK) Down 9.5% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    OPKO Health (OPK) Q4 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    OPKO Health's (OPK) fourth-quarter results benefit from strength in diagnostics.

    OPKO Health (OPK) Q4 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    OPKO Health (OPK) delivered earnings and revenue surprises of 25.00% and 13.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    OPKO Health (OPK) to Report Q4 Earnings: What's in Store?

    by Zacks Equity Research

    OPKO Health's (OPK) fourth-quarter results are likely to reflect solid performance from Services and Products segment and RAYALDEE.

    OPKO Health's (OPK) BioReference Extends Digital Health Access

    by Zacks Equity Research

    OPKO Health's (OPK) BioReference introduces an in-home, fully-integrated digital platform providing access to diagnostic services.

    OPKO Health (OPK) Outpaces Stock Market Gains: What You Should Know

    by Zacks Equity Research

    OPKO Health (OPK) closed the most recent trading day at $4.48, moving +1.82% from the previous trading session.

    OPKO Health's (OPK) BioReference Starts Fan Testing Program

    by Zacks Equity Research

    OPKO Health's (OPK) BioReference commences mandatory, large-scale COVID-19 testing programs for fans for AFC Division Wild Card playoff game.

    OPKO Health (OPK) Loses 16.2% Despite In-Line Q3 Earnings

    by Zacks Equity Research

    OPKO Health's (OPK) third-quarter results benefit from increase in RAYALDEE prescriptions.